<DOC>
	<DOCNO>NCT00333489</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety tolerability valsartan+amlodipine association patient mild moderate essential hypertension , comparison amlodipine alone . Patients mild moderate essential hypertension [ grade 1 2 WHO classification ( 8 ) ] . The diastolic blood pressure threshold inclusion study 95 mmHg , patient likely benefit association therapy patient low diastolic blood pressure . For safety reason , patient severe hypertension ( grade 3 WHO classification ) include study . Moreover , patient develop severe hypertension ( MSDBP &gt; 110 mmHg and/or MSSBP &gt; 180 mmHg ) open-label treatment phase discontinue study .</brief_summary>
	<brief_title>Comparative Study Valsartan Amlodipine Versus Amlodipine Alone Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<criteria>Incl Patients mild moderate essential hypertension ( grade 1 2 WHO classification ) . Patients essential diastolic hypertension measure standard aneroid mercury column sphygmomanometer show MSDBP &gt; 95 mmHg &lt; 110 mmHg MSSBP &lt; 180 mmHg . Severe hypertension ( grade 3 WHO classification : DBP &gt; = 110 mmHg and/or SBP â‰¥ 180 mmHg ) malignant hypertension . Inability completely discontinue antihypertensive medication safely period least 2 week require protocol . Evidence secondary form hypertension , coarctation aorta , hyperaldosteronism , unilateral bilateral renal artery stenosis , Cushing 's disease , pheochromocytoma , polycystic kidney disease , etc .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>valsartan</keyword>
	<keyword>amlodipine</keyword>
	<keyword>hypertension</keyword>
</DOC>